Twenty-seven years of phase III trials for patients with extensive disease small-cell lung cancer: disappointing results.
BACKGROUND: Few studies have formally assessed whether treatment outcomes have improved substantially over the years for patients with extensive disease small-cell lung cancer (ED-SCLC) enrolled in phase III trials. The objective of the current investigation was to determine the time trends in outco...
Main Authors: | Isao Oze, Katsuyuki Hotta, Katsuyuki Kiura, Nobuaki Ochi, Nagio Takigawa, Yoshiro Fujiwara, Masahiro Tabata, Mitsune Tanimoto |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2009-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC2773043?pdf=render |
Similar Items
-
Treatment-related death in patients with small-cell lung cancer in phase III trials over the last two decades.
by: Nobuaki Ochi, et al.
Published: (2012-01-01) -
Role of survival post-progression in phase III trials of systemic chemotherapy in advanced non-small-cell lung cancer: a systematic review.
by: Katsuyuki Hotta, et al.
Published: (2011-01-01) -
Rapid on-site evaluation with BIOEVALUATOR® during endobronchial ultrasound-guided transbronchial needle aspiration for diagnosing pulmonary and mediastinal diseases
by: Daisuke Minami, et al.
Published: (2014-01-01) -
Mechanisms of Acquired Resistance to ALK Inhibitors and the Rationale for Treating ALK-positive Lung Cancer
by: Hideko Isozaki, et al.
Published: (2015-04-01) -
The Role of STAT3 in Non-Small Cell Lung Cancer
by: Daijiro Harada, et al.
Published: (2014-03-01)